Available Technology

Tempol: A Commercially Available Nitroxide as Cancer Therapeutics

The invention is the discovery that a commercially available stable nitroxide, namely TEMPOL can effectively reduce the level of hypoxia-inducible transcription factor (HIF)-2alpha. Elevated HIF-2alpha is associated with clear cell kidney cancer characterized by mutation of the VHL tumor suppressor gene and with many other cancers. Therefore, TEMPOL can potentially be developed into a cancer drug to treat patients with elevated HIF-2alpha, whether due to compromised VHL function or not.

Patent Abstract: 

The invention is the discovery that a commercially available stable nitroxide, namely TEMPOL can effectively reduce the level of hypoxia-inducible transcription factor (HIF)-2alpha. Elevated HIF-2alpha is associated with clear cell kidney cancer characterized by mutation of the VHL tumor suppressor gene and with many other cancers. Therefore, TEMPOL can potentially be developed into a cancer drug to treat patients with elevated HIF-2alpha, whether due to compromised VHL function or not.

Benefits 
Animal data confirms effectiveness of TEMPOL against cancer support
Inventors: 

William Marston Linehan

Patent Number: 
PCTUS2010058332 US Application No. 13512,665
Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin